MedLife launches the EarlyCDT® test, which allows early detection of lung cancer by identifying specific autoantibodies, available in all its units.
Delia Niculescu
Current Affairs
foto:shutterstock
Always see our news on Google
MedLife Group, the leading private healthcare provider in Romania, has introduced the EarlyCDT® test, a blood-based immunologic test for the early detection of lung cancer. It identifies autoantibodies produced by the body up to 4 years before visible lesions appear. The test is non-invasive and is mainly targeted at people with risk factors, with a turnaround time of about 15 days. Studies show that the use of this test reduces late-stage diagnoses by 36%, increasing the chances of survival. MedLife reaffirms its commitment to innovation in laboratory medicine.
Sources
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Inovație în medicina de laborator: MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
MedLife introduce în premieră în România testul EarlyCDT®, un test de sânge pentru depistarea timpurie a cancerului pulmonar
Latest News
14:22
Nolan's "Odyssey", sold out until September at the only cinema in France with IMAX 70mm
14:05
Two Moroccan citizens were found unconscious in the trailer of a truck on DN 5, after they illegally entered Romania.
13:47
The Foxtrot network, linked to Iran, recruits teenagers for crimes in Europe: the case of Atilla Azimov
13:21
Meteoplus: The drought in Central Europe keeps the Danube at critical levels, despite the abundant rainfall in Romania
12:57
Latvia has closed its border with Belarus citing technical reasons amid an increase in illegal crossings.
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
